# An Efficacy and Safety Study of Anti-TNF Monoclonal Antibody in Patients With Fistulizing Crohn's Disease

> **NCT00269841** · PHASE3 · COMPLETED · sponsor: **Centocor, Inc.** · enrollment: 94 (actual)

## Conditions studied

- Crohn Disease

## Interventions

- **DRUG:** Infliximab 10 mg/kg
- **DRUG:** Infliximab 5 mg/kg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00269841
- **Lead sponsor:** Centocor, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1996-05
- **Primary completion:** 1998-02
- **Final completion:** 1998-02
- **Target enrollment:** 94 (ACTUAL)
- **Last updated:** 2014-11-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00269841

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00269841, "An Efficacy and Safety Study of Anti-TNF Monoclonal Antibody in Patients With Fistulizing Crohn's Disease". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00269841. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*